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AbstrACt
Introduction Although evidence exists for the efficacy of 
psychosocial interventions in preventing depression, little 
is known about its prevention through online interventions. 
The objective of this study is to conduct a systematic 
review and meta-analysis of randomised controlled trials 
assessing the effectiveness of online interventions in 
preventing depression in heterogeneous populations.
Methods and analysis We will conduct a systematic 
review and meta-analysis of randomised controlled 
trials that will be identified through searches of PubMed, 
PsycINFO, WOS, Scopus, OpenGrey, Cochrane Central 
Register of Controlled Trials,  ClinicalTrials. gov and 
Australia New Zealand Clinical Trials Register . We will 
also search the reference lists provided in relevant studies 
and reviews. Experts in the field will be contacted to 
obtain more references. Two independent reviewers will 
assess the eligibility criteria of all articles, extract data 
and determine their risk of bias (Cochrane Collaboration 
Tool). Baseline depression will be required to have been 
discarded through standardised interviews or validated 
self-reports with standard cut-off points. The outcomes 
will be the incidence of new cases of depression and/
or the reduction of depressive symptoms as measured 
by validated instruments. Pooled standardised mean 
differences will be calculated using random-effect models. 
Heterogeneity and publication bias will be estimated. 
Predefined sensitivity and subgroup analyses will be 
performed. If heterogeneity is relevant, random-effect 
meta-regression will be performed.
Ethics and dissemination The results will be 
disseminated through peer-reviewed publication and 
will be presented at a professional conference. Ethical 
assessment is not required as we will search and assess 
existing sources of literature.
trial registration number CRD42014014804; Results.
IntroduCtIon 
Depression is a common, resource-con-
suming and disabling mental disorder that 
reduces life expectancy.1 There are currently 
322 million people with depression in the 
world.2 The average lifetime and 12-month 
prevalence estimates of DSM-IV Major 
Depression Episode in high-income coun-
tries are 14.6% and 5.5%, respectively.3 In 
the last 10 years, the burden of major depres-
sion measured as years lived with disability 
(YLD) increased by 17.8%, ranking third in 
the world in disease burden3 and will rank 
first in high-income countries by 2030.4 In 
addition, depression is the primary cause of 
disability in the world attributable to mental 
and substance use disorders.5 
Current treatments for depression show 
several constraints such as accessibility issues, 
limited efficacy or lack of adherence.6–8 Even 
if it was possible to provide appropriate treat-
ments to all persons affected by a depressive 
disorder, the effect on averting YLD would 
strengths and limitations of this study
 ► This is the first systematic review and meta-anal-
ysis of randomised controlled trials assessing the 
effectiveness of online interventions in preventing 
depression in a heterogeneous population.
 ► The study will be conducted according to Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses guidelines for reporting systematic reviews 
and meta-analysis to meet the highest scientific 
quality.
 ► The effect size, robustness and quality of evidence 
found in this meta-analysis will help determine 
whether depression can be prevented through on-
line interventions.
 ► This study will have the limitations inherent to any 
systematic review and meta-analysis, such as the 
loss of information on outcome variables, or the as-
sumption that the evaluation techniques are consis-
tent across studies.
 ► The number and quality of the randomised con-
trolled trials included, heterogeneity and occurrence 
of publication bias might limit the interpretation of 
results.
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be limited because of the steady influx of new cases of 
depression.9 For all these reasons, the burden of depres-
sion can only be reduced by 20%–30%.10 Prevention may 
offer new possibilities to reduce the disease burden of 
depressive disorders.11 12
Hundreds of randomised controlled trials (RCTs) and 
dozens of systematic reviews (SRs)/meta-analyses (MA) 
have been published on interventions to prevent depres-
sion.13–17 A systematic review of SR/MA of psychological 
and/or educational interventions to prevent depression 
included 12 SR/MA (156 non-repeated trials and 56 158 
participants) and found a small-moderate preventive 
effect.18 If preventive interventions reach a significant 
part of the population, even if this effect size is small, the 
impact on health, quality of life and healthcare costs could 
be relevant. From this point of view, scalability is crucial 
to prevention interventions. Solutions may leverage tech-
nological advances, such as mHealth-based counselling, 
computer and web-based resources.19
Interest in online prevention programmes for depres-
sion has increased substantially in recent years.20–22 
Online interventions offer some advantages over face-
to-face interventions for both patients and the health 
system. Its advantages include greater intimacy, lower 
economical costs, the opportunity of joining the inter-
vention at any time and place, easy access to a wider 
range of people (disabled population, rural areas, 
etc) and a reduction in the time of waiting, among 
others.23–27
So far, three SR/MA on the effectiveness of online 
interventions in preventing mental disorders have been 
published.28–30 To our knowledge, these previous reviews 
have some limitations. One28 was focused on several 
mental disorders altogether (eating, anxiety, insomnia, 
post-traumatic stress, depression and common mental 
health disorders) and included only four trials on the 
prevention of depression. A limitation was the inclu-
sion of some studies that only reported mean scores and 
did not clearly state that participants did not exceed 
clinical cut-offs at baseline, thus making it difficult to 
separate treatment from prevention. The other29 was 
focused on the online cognitive behavioural therapy 
for subthreshold depression, which restricts its infer-
ence for that kind of psychotherapy and only for a type 
of prevention, indicated prevention; not addressed, 
thus, universal and selective prevention strategies. In 
addition, new RCTs on online interventions for the 
prevention of depression have been published.31–35 
The last SR/MA30 found a small preventive effect of the 
eHealth interventions to prevent anxiety and depres-
sion; however, there were some exclusion criteria which 
limited their inferences: age (18–64 years), language 
(English), date (from 2000) and non-specific popula-
tion (eg, postnatal or comorbid). Therefore, the objec-
tive of this study will be to conduct a systematic review 
and meta-analysis of RCTs assessing the effectiveness 
of online interventions in preventing depression in 
heterogeneous populations.
MEthods And AnAlysIs
We followed Preferred Reporting Items for System-
atic review and Meta-Analysis Protocols guidelines for 
reporting systematic reviews and meta-analysis proto-
cols.36 The protocol of this study has already been regis-
tered with the International Prospective Register of 
Systematic Reviews, (PROSPERO) on 20 November 2014 
and was last updated on 23 November 2017 (registration 
number: CRD42014014804).
Eligibility criteria
The rationale for the inclusion and exclusion criteria 
outlined below is to obtain a comprehensive overview of 
the RCTs performed so far assessing the effectiveness of 
online interventions in preventing depression in different 
populations and settings.
study design
We will focus on RCTs since this design provides more 
evidence on causality and is considered a gold standard 
for clinical trials.37 Cluster randomised trials will only be 
included if there are at least two intervention and control 
sites and outcomes are reported adjusted for clustering 
effect. Controlled non-randomised clinical trials or 
before-after trials will be excluded.
Participants and exclusion of depression at baseline
Participants may have any sociodemographic (age, sex, 
etc) or clinical (healthy, chronic physical illness, etc) 
characteristic and all settings (community, schools, 
primary care, etc) will be considered. To make a clear 
distinction between the effectiveness of prevention inter-
ventions from that of treatments, baseline depression will 
be required to have been discarded through standardised 
interviews (eg, Composite International Diagnostic Inter-
view, CIDI) or validated self-reports with standard cut-off 
points (eg, Beck Depression Inventory, BDI-II). In a 
preventive context, the most useful parameter of validity 
of a diagnostic instrument to discard depression at base-
line is the ‘negative predictive value’ (NPV): probability 
of having a depressive disorder when the result of a diag-
nostic tool is negative. The NPV is influenced by three 
main parameters: cut-off selected, sensitivity associated 
with that cut-off and prevalence of depressive disorders in 
the reference population of the study. Higher sensitivity, 
lower cut-off and prevalence will increase the NPV and 
minimise false negatives. Structured standardised inter-
views generally have greater validity than symptom scales 
and, therefore, the former are preferable. However, 
structured standardised interviews tend to have greater 
specificity than sensitivity; therefore, false positives will be 
minimised at the expense of increasing false negatives. 
From this point of view, a symptoms scale with a diagnostic 
threshold associated with high sensitivity could guarantee 
as valid as a structured standardised interview, especially 
if the study is carried out on a reference population with 
a low prevalence of depressive disorders, as it is usual in 
prevention studies.
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type of interventions
We will only include RCTs assessing the effectiveness of 
psychosocial and/or educational since they share the 
same mechanism of action that facilitates changes in atti-
tudes and behaviours and because most interventions to 
prevent depression are of this type. Educational interven-
tions provide information sessions or fact sheets, whereas 
psychosocial interventions attempt to change how people 
think and behave by using a variety of strategies (eg, 
cognitive-behavioural or interpersonal). However, in real 
practice psychosocial and educational interventions can 
overlap, being difficult to distinguish them. Interventions 
must be accessible online and the study should include at 
least an internet-delivered intervention programme. If no 
online intervention is implemented in any of the exper-
imental arms, the RCT will be excluded. Intervention 
arms where active pharmacological therapies are admin-
istered will also be excluded.
Comparators
Comparator groups could be ‘only assessments’, ‘no 
treatment’, ‘usual care’, ‘waiting list’ or any type of active 
control which has no effect on depression. All types of 
placebo (psychological or pill) will also be accepted 
as comparators. Comparator arms which intervention 
(psychological, physical or pharmacological) has been 
proven to be effective in preventing depression will also 
be excluded.
outcomes
RCTs which primary or secondary outcomes were the 
incidence of new cases of depression and/or the reduc-
tion of depression symptoms will be included. Outcomes 
will be required to have been measured by standardised 
interviews or validated symptom scales. When more than 
a symptom scale has been used to measure outcomes 
in an RCT, the data from the highest validity scale will 
be employed. If the validation data of the scales, in the 
country and setting where the study was conducted, are 
not reported in the article, they will be searched in the 
literature and other sources. The parameters that will be 
used to select the scale of symptoms are higher Youden's 
J statistic (J=sensitivity+specificity – 1), Cronbach alpha 
and intraclass correlation coefficient (test–retest) and 
sensitivity to change over time (yes/no/not available). 
For each trial, the scale of symptoms that provide more 
validation data and of higher quality will be chosen. If 
depression outcomes are measured together with other 
outcomes (eg, anxiety) and data are not provided sepa-
rately, RCTs will be excluded.
Information sources and search strategy
A literature search of the following electronic databases 
will be carried out: PubMed, PsycINFO, WOS, Scopus and 
Cochrane Central Register of Controlled Trials. Search 
will be supplemented by searching for trial protocols on 
ClinicalTrials. gov and Australia New Zealand Clinical 
Trials Register. We will also examine OpenGrey (System 
for Information on Grey Literature in Europe), where 
grey literature is indexed. PROSPERO will be searched 
for ongoing or recently completed systematic reviews. To 
ensure literature saturation, we will also review reference 
lists from relevant systematic reviews and meta-analysis 
and those from the RCTs included in our SR/MA. In addi-
tion, expert authors will be contacted in order to identify 
missing articles in our search. Literature search strategies 
will be developed using medical subject headings and 
text words related to prevention, depression and internet 
intervention. No limits will be imposed on study publi-
cation language or publication date. The search will be 
updated toward the end of the review. A draft MEDLINE 
search strategy in PICOS format is included in online 
supplementary file. We will adapt the MEDLINE strategy 
to the syntax and subject headings of the other databases.
study selection
The entire selection process will be conducted inde-
pendently by two reviewers. After elimination of dupli-
cate studies, all records will be reviewed. Based on their 
titles and abstracts, the studies that do not meet inclu-
sion criteria will be ruled out. The full text of the studies 
selected as potentially relevant will be reviewed for 
further assessment. Any disagreements will be discussed 
and resolved by consensus or by a third independent 
reviewer, if necessary. We will seek additional information 
from corresponding authors when necessary to resolve 
questions about eligibility. We will record the reasons 
for excluding trials. The reviewers will not be blind to 
the journal titles or the study authors or institutions. 
Inter-agreement of the total selection will be assessed 
using kappa,38 which can be interpreted as follows: <0.20 
as poor, 0.21–0.40 as fair, 0.41–0.60 as moderate, as 0.61–
0.80 as good and 0.81–1.00 as excellent.
data extraction
Data extraction from each eligible study will be conducted 
independently by two reviewers. Any disagreement will be 
discussed and resolved by consensus or by a third inde-
pendent reviewer. We will also contact authors to get 
incomplete or unclear information, where appropriate. 
Abstracted data will include author/year and country; 
setting, target population characteristics (age, sex, etc) 
and type of prevention (universal, selective or indicate); 
sample size (control/intervention); exclusion of depres-
sion criteria at baseline and validated instruments used; 
orientation and intervention type and intervention details 
in both experimental and control groups (type, modes of 
application, frequency, intensity and level of adherence); 
prevention depression outcomes and validated instru-
ments used; and all follow-up provided from the RCTs. 
Whenever possible, we will use results from intention-to-
treat analysis.
risk of bias
The quality of the articles will be assessed using the 
six criteria of risk bias proposed by the Cochrane 
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Collaboration tool: random sequence generation, 
allocation concealment, blinding of participants and 
personnel, blinding of outcome assessment, incomplete 
outcome data (eg, dropouts and withdrawals) and selec-
tive reporting. To manage the risk of bias as a quantitative 
variable in meta-regression, it will be assessed by assigning 
the zero points to low-risk criteria, one to unclear and 
two to high-risk criteria. Therefore, the highest risk of 
bias score will be 12 and the lowest 0. The risk of bias 
will be assessed independently by two reviewers. In case 
of disagreement, a third reviewer will be consulted. The 
inter-agreement will be rated using intraclass correla-
tion coefficient.38 The original study investigators will be 
contacted for more information, when necessary.
Assessment of publication bias
Publication bias will be evaluated by inspecting the funnel 
plot on the primary outcome measure and by Duval and 
Tweedie’s trim-and-fill procedure,39 which yields an esti-
mate of the effect size after adjusting for publication bias. 
The funnel plot is expected to be symmetric, equally 
dispersed on the general effect. If there are missing 
studies, the trim and fill procedure imputes these studies 
and adds them to the analysis. We will also perform Begg 
and Mazumdar rank correlation40 and Egger’s test.41 If 
asymmetry is potentially caused by publication bias, we 
expect to see high SEs (small studies) associated with 
larger effect sizes.
Patient and public involvement
No patients or public will be involved in the study.
statistical analysis
All statistical analyses will be performed using the Compre-
hensive Meta-Analysis (CMA) software package, V.2.2.021 
and STATA-Release V.14.2. Standardised mean difference 
(SMD) will be used as effect size as most RCTs included 
in our meta-analysis are expected to report differences in 
symptoms of depression. For each study, we will first calcu-
late the SMD by merging the SMD at different follow-up 
times into a single average estimate. We then will calcu-
late the pooled SMD of all RCTs as well as its 95% CI. 
If some RCT only reports new cases of depression’ (inci-
dence of depression), CMA will be used to obtain the 
equivalent SMD. Negative SMDs (between intervention 
and control group) will indicate a better outcome (reduc-
tion of depressive symptoms) in the intervention group. 
Following the interpretation proposed by Cohen for this 
effect size: −0.2 is small; −0.5 medium and −0.8 large.42 
We will inflate the SEs of the nested comparisons in the 
same RCT following the suggestions of Cates.43 A priori, 
we selected a random-effects model for our meta-analysis 
under the assumption that the RCTs to be included in our 
study will be performed in heterogeneous ‘populations’ 
that may differ from each other.44
To test the heterogeneity of effect sizes, I2 and its 
95% CI will be calculated and expressed as percent-
ages, where a value of 0%–40% might be unimportant 
heterogeneity, 30%–60% moderate, 50%–90% substantial 
and 75%–100% considerable.44 We will also calculate the 
Cochran’s Q statistic and its p value.
We will perform the following sensitivity analyses: at 
first and last follow-up, using fixed effects and Hedges’g 
and excluding some RCTs from analysis (eg, those which 
cause the greatest increase in heterogeneity).
We will use a mixed-effects model for subgroup analyses 
based on a set of variables selected a priori, as follows: type 
of prevention (universal, selective or indicated), preven-
tion of depression as primary or secondary outcome, type 
of outcome measure (symptoms scale vs standardised 
diagnostic interview), country, population age, setting 
(school, primary care, etc), comparator (waiting list, usual 
care, active control), intervention orientation (Cogni-
tive Behavioural Therapy, other), intervention format, 
intervention guidance (guided or unguided), number of 
sessions or impacts, follow-up, level of usability or adher-
ence (if it was measured), sample size and risk of bias.
Random-effect meta-regressions will be performed to 
investigate whether there are differences in effect sizes 
over time or according to the risk of bias. Normality of 
quantitative variables will be verified by the skewness and 
kurtosis normality test prior to inclusion in meta-regres-
sion analysis45; transformations will be conducted, when 
appropriate, to get approximation to normality. If signif-
icant heterogeneity is observed, the covariables with a 
p<0.15 which were not removed from the model due 
to collinearity will be also included in meta-regression 
models. Risk of bias and sample size will be forced into 
meta-regression models to adjust for them, the latter only 
in case of detection of publication bias. SE and CIs will 
be calculated using the Knapp and Hartung method.46 
P values will be calculated using Higgins and Thompson47 
permutation test approach, taking into account multi-
plicity adjustment, when necessary. A normal probability 
plot of standardised shrunken residuals will be used to 
estimate the goodness of fit of meta-regression models.
the quality of evidence
The quality of evidence in the domains of risk of bias, 
consistency, directness, precision and publication bias 
will be assessed using the Grading of Recommendations 
Assessment, Development and Evaluation working group 
methodology.48 Additional domains may be considered, 
where appropriate.
Ethics and dissemination
The results will be disseminated through peer-reviewed 
publication and will be presented at a professional confer-
ence. Ethical assessment is not required as we will search 
and assess existing sources of literature.
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